School of Medicine
Showing 11-20 of 29 Results
Donna Peehl, PhD
Professor (Research) of Urology, Emerita
Current Research and Scholarly InterestsMy research focuses on the molecular and cellular biology of the human prostate. Developing realistic experimental models is a major goal, and primary cultures of prostatic epithelial and stromal cells are my main model system. Our discoveries are relevant to prevention, detection, diagnosis and treatment of benign and malignant prostatic diseases.
Susy Yuan-Huey Hung Professor
Current Research and Scholarly InterestsMolecular mechanisms of targeted therapy resistance in breast and other cancers
Boston Scientific Applied Biomedical Engineering Professor and Professor of Radiology, Emeritus
Current Research and Scholarly InterestsBroadly, Dr. Pelc is interested in the physics, engineering and mathematics of medical imaging, especially computed tomography, digital x-ray imaging, magnetic resonance imaging, and hybrid multimodality systems. His current research is concentrated in the development of computed tomography systems with higher image quality and dose efficiency, in the characterization of system performance, and in the development and validation of new clinical applications.
VJ Periyakoil, Geriatrics, Hospice & Palliative Medicine
Professor of Medicine (Primary Care and Population Health)
Current Research and Scholarly InterestsMy research focuses on the intersection of biological, psychosocial and cultural aspects of care of persons with chronic and serious illnesses including dementia.
Claudia Katharina Petritsch
Associate Professor (Research) of Neurosurgery
Current Research and Scholarly InterestsThe Petritsch lab broadly investigates underlying causes for the intra-tumoral heterogeneity and immune suppression in brain tumors from a neuro-developmental perspective. Defective cell fate decisions fuel the intra-humoral heterogeneity and plasticity in human brain tumors and may contribute to immune suppression. We use patient-derived models as avatars to study how brain cells control the fate of their progeny, whereby we unravel novel points of vulnerabilities in brain tumor cells.
Emma Pfeiffer Merner Professor of Medical Sciences
Current Research and Scholarly InterestsThe major focuses of our research is to understand the molecular basis of inherited Parkinson's Disease (PD) and to elucidate the molecular mechanisms by which proteins and cholesterol are transported between specific membrane compartments. We focus on the LRRK2 kinase that is inappropriately activated in PD and how it phosphorylates Rab GTPases, blocking the formation of primary cilia in culture and specific regions of the brain.
Associate Professor of Medicine (Oncology) and of Otolaryngology - Head & Neck Surgery
Current Research and Scholarly InterestsClinical Interests: general oncology, head and neck cancer Research Interests: chemoprevention trials and combined modality approaches to head and neck cancer
Associate Professor (Research) of Radiology (Cancer Early Detection-Canary Center)
Current Research and Scholarly InterestsThe Pitteri laboratory is focused on the discovery and validation of proteins that can be used as molecular indicators of risk, diagnosis, progression, and recurrence of cancer. Proteomic technologies, predominantly mass spectrometry, are used to identify proteins in the blood that are differentially regulated and/or post-translationally modified with disease state. Using human plasma samples, tumor tissue, cancer cell lines, and genetically engineered mouse models, the origins of these proteins are being investigated. A major goal of this research is to define novel molecular signatures for breast and ovarian cancers, including particular sub-types of these diseases. This laboratory is also focused on the identification of proteins with expression restricted to the surface of cancer cells which can be used as novel targets for molecular imaging technologies.
Philip A. Pizzo, M.D.
David and Susan Heckerman Professor, Emeritus
BioPhilip Pizzo, MD, is the David and Susan Heckerman Professor and Founding Director of the Stanford Distinguished Careers Institute. Pizzo served as Dean of the Stanford School of Medicine from April 2001 to December 1, 2012, where he was also the Carl and Elizabeth Naumann Professor of Pediatrics and of Microbiology and Immunology. Dr. Pizzo has devoted much of his distinguished medical career to the diagnosis, management, prevention and treatment of childhood cancers and the infectious complications that occur in children whose immune systems are compromised by cancer and AIDS. He has also been a leader in academic medicine, championing programs and policies to improve the future of science, education and healthcare in the US and beyond.
Pizzo received his MD degree with Honors and Distinction in Research from the University of Rochester in 1970, and completed an internship and residency at Children’s Hospital Medical Center in Boston, a teaching fellowship at Harvard Medical School, and a clinical and research fellowship in pediatric oncology at the National Cancer Institute. Pizzo served as head of the Institute’s infectious disease section, chief of the NCI’s pediatric department, and acting scientific director for NCI’s Division of Clinical Sciences between 1973 and 1996. Before joining Stanford in 2001, he was the physician-in-chief of Children’s Hospital in Boston and Chair of the Department of Pediatrics at Harvard Medical School, where he was also the Thomas Morgan Rotch Professor of Pediatrics.
Dr. Pizzo is the author of more than 615 scientific articles and 16 books and monographs, including Principles and Practice of Pediatric Oncology, the Seventh Edition of which was published in 2015.
Pizzo has received numerous awards and honors, among them the Public Health Service Outstanding Service Medal in 1995, the Barbara Bohen Pfiefer Award for Scientific Excellence in 1991, the Elizabeth Kubler-Ross Award in 2008, the Ronald McDonald Charities “Award of Excellence” in 2009, and the John and Emma Bonica Public Service Award in 2013. He is the 2012 recipient of the John Howland Award, the highest honor for lifetime achievement bestowed by the American Pediatric Society. He has been elected to a number of prestigious organizations and societies, including the Association of American Physicians, the American Society of Clinical Investigation, the American Pediatric Society and the Institute of Medicine of the National Academy of Sciences, where he was also elected to the Governing Council. The IOM became the National Academy of Medicine in 2015. He has served as Chair of the Association of Academic Health Centers and Chair of the Council of Deans of the Association of American Medical Colleges, and was elected to the Board of Directors of the American Society for Clinical Oncology and the Infectious Diseases Society of America. He was President of the International Immunocompromised Host Society (1998-2011). He served on the Governing Board for the California Institute of Regenerative Medicine from 2004-2012. In 2009 he was elected to the Board of Trustees of the University of Rochester and the Board of Overseers of Koc University in Istanbul, Turkey. He was a member of the Board of Directors of MRI Interventions (2013-2017) and the Academic Advisory Council for Merritt Hawkins (2015-present). In 2014 he was elected to the Board of Directors of the Ludwig Institute for Cancer Research and in 2015 he was elected to the Board of Directors of Global Blood Therapeutics. He also serves as Editor-in-Chief of Current Opinion in Pediatrics.
Sylvia K. Plevritis, PhD
Professor of Biomedical Data Science and of Radiology (Integrative Biomedical Imaging Informatics at Stanford)
Current Research and Scholarly InterestsMy research program focuses on computational modeling of cancer biology and cancer outcomes. My laboratory develops stochastic models of the natural history of cancer based on clinical research data. We estimate population-level outcomes under differing screening and treatment interventions. We also analyze genomic and proteomic cancer data in order to identify molecular networks that are perturbed in cancer initiation and progression and relate these perturbations to patient outcomes.